Changes of hemodynamics and O2 transport associated with the perfluorochemical blood substitute, Fluosol-DA.
Hemodynamic, arterial O2 tension (PaO2) and transcutaneous O2 tension (PtcO2) changes associated with the infusion of 500 ml of Fluosol-DA were evaluated in 14 decerebrated patients. Flow-directed pulmonary artery catheters and the Clark-type oxygen electrode manufactured by Hoffmann-La Roche were utilized. The marked improvement of cardiovascular variables along with marked increases in PaO2 and PtcO2 may indicate a marked increase in skin circulation by the infusion of Fluosol. One patient exhibited a hypotensive episode during the infusion, which lasted only a short time, disappeared spontaneously, and did not prohibit the further infusion of Fluosol. We still consider that Fluosol will be clinically useful for increasing oxygen capacity and improving overall hemodynamic status as well as individual organ circulation.
D000328:Adult; D000368:Aged; D003422:Critical Care; D003655:Decerebrate State / Q000188:drug therapy*; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D005466:Fluorocarbons / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D010101:Oxygen Consumption / Q000187:drug effects
D004338:Drug Combinations; D005466:Fluorocarbons; D006895:Hydroxyethyl Starch Derivatives; C017323:glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination; D010100:Oxygen